SER

Serina Therapeutics, Inc. · AMEX

Sector Commercial Services
Industry Miscellaneous Commercial Services
Website erinatherapeutics.com
Employees(FY) -
ISIN US81751A1088

Performance

+26.02%

+3.56%

-39.4%

-36.53%

-61.37%

YTD

-62.11%

Profile

Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama.

Advanced Technical Analysis

Technical Analysis of SER 2024-12-24

The stock indicators reflect a bearish sentiment overall, with the Moving Average Score at 23, the Oscillators Score at 43 indicating a neutral stance, and the Technical Score at 33 reinforcing the bearish outlook. This combination suggests a lack of strong bullish momentum, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SER

Stock Rank

Recent News & Updates

2024-12-15 17:00
Serina Therapeutics to Present at Tribe Public's Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024(Globenewswire)
2024-12-10 17:05
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit(Yahoo Finance)
2024-12-10 17:05
Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity and Toxicity Summit(Globenewswire)
2024-12-02 04:22
Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients(Globenewswire)
2024-11-12 04:00
Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights(Globenewswire)
2024-11-11 04:40
Serina Therapeutics Makes Grants to New Employees Under Inducement Plan(Globenewswire)
2024-10-01 20:30
Serina Therapeutics to Present at the 14th Annual Injectables Summit(Globenewswire)
2024-09-04 06:42
Serina Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-20 07:01
Director Gregory Bailey Acquires 19,200 Shares of Serina Therapeutics Inc (SER)(Yahoo Finance)
2024-08-09 04:15
Serina Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights(Globenewswire)
2024-07-28 20:30
Serina Therapeutics to Present Novel Data on POZ-Lipid Technology Potentially Enhancing Safety and Efficacy of mRNA LNP Formulations at the 4th mRNA-Based Therapeutics Summit(Globenewswire)
2024-07-18 05:00
Serina Therapeutics Appoints Srini Tenjarla, Ph.D. as Senior Vice President of CMC and Formulation(Globenewswire)
2024-05-14 19:30
Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuseÂ® for Advanced Parkinsons Disease(Yahoo Finance)
2024-05-14 04:05
Serina Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights(Globenewswire)
2024-04-17 04:05
Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman(Globenewswire)
2024-03-26 05:04
Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics(Yahoo Finance)
2024-03-22 05:27
AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results(Globenewswire)
2023-11-16 19:00
Serina Therapeutics Announces POZ Polymer Technology License Agreement with Pfizer(Yahoo Finance)
2023-11-14 03:05
AgeX Therapeutics Reports Third Quarter 2023 Financial Results(Yahoo Finance)
2023-08-29 19:00
Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement(Yahoo Finance)
2023-08-14 04:05
AgeX Therapeutics Reports Second Quarter 2023 Financial Results(Yahoo Finance)
2023-07-24 06:28
AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock(Yahoo Finance)
2023-07-21 05:32
AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock(Yahoo Finance)
2023-05-23 04:05
AgeX Therapeutics Announces Appeal of NYSE American Determination(Yahoo Finance)
2023-05-12 04:05
AgeX Therapeutics Reports First Quarter 2023 Financial Results(Yahoo Finance)
2023-04-26 04:05
AgeX Therapeutics Receives Stock Exchange Deficiency Letter(Yahoo Finance)
2023-03-31 04:05
AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results(Yahoo Finance)
2022-11-25 02:41
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements(Yahoo Finance)
2022-11-10 03:05
AgeX Therapeutics Reports Third Quarter 2022 Financial Results(Yahoo Finance)
2022-08-12 04:05
AgeX Therapeutics Reports Second Quarter 2022 Financial Results(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.